Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Consensus Rating of “Moderate Buy” by Analysts

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has received an average rating of “Moderate Buy” from the eight ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $78.8571.

A number of equities analysts recently weighed in on the company. Citigroup raised their price objective on Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. BTIG Research increased their price target on shares of Establishment Labs from $81.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, December 31st. Needham & Company LLC restated a “buy” rating and issued a $84.00 price objective on shares of Establishment Labs in a report on Monday, January 12th. Mizuho upped their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Finally, Canaccord Genuity Group lifted their target price on shares of Establishment Labs from $72.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $73.54 on Friday. The firm’s 50 day moving average is $70.40 and its 200 day moving average is $55.55. The stock has a market capitalization of $2.14 billion, a P/E ratio of -25.89 and a beta of 0.99. Establishment Labs has a 12 month low of $26.56 and a 12 month high of $78.24. The company has a current ratio of 3.33, a quick ratio of 2.10 and a debt-to-equity ratio of 15.06.

Institutional Investors Weigh In On Establishment Labs

Large investors have recently made changes to their positions in the business. HRT Financial LP bought a new position in Establishment Labs in the fourth quarter worth about $7,653,000. Brooklyn Investment Group purchased a new position in shares of Establishment Labs during the 4th quarter worth approximately $220,000. Swiss National Bank raised its position in shares of Establishment Labs by 1.8% in the 4th quarter. Swiss National Bank now owns 34,200 shares of the company’s stock worth $2,492,000 after acquiring an additional 600 shares in the last quarter. Polen Capital Management LLC purchased a new position in shares of Establishment Labs in the 4th quarter valued at approximately $1,274,000. Finally, Nuveen LLC lifted its stake in shares of Establishment Labs by 12.3% in the 4th quarter. Nuveen LLC now owns 352,074 shares of the company’s stock valued at $25,659,000 after purchasing an additional 38,487 shares during the period. 72.91% of the stock is currently owned by institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.